Researchers have found that female patients with oesophagus and stomach cancer are likely to survive longer than male patients but experience more nausea vomiting and diarrhoea during therapy. The findings of a latest UK study could potentially help in managing patients and also highlight who are more at risk against specific side effects. We tend to use a standard treatment approach for managing oesophageal and stomach cancer. What this research suggests is that there are significant differences between male and female patients not only in how they react to chemotherapy but also how long they survive following treatment for their
